What is the difference between avatropopag and eltrombopag?

The differences between avatrombopag and eltrombopag are mainly reflected in the following aspects:

1. Chemical structure

Avatrombopag and eltrombopag differ in their chemical structure. Eltrombopag has a hydrazide structure, which can easily form stable chelates with metal cations, thereby reducing drug exposure and efficacy in the blood. In contrast, avatrombopag does not have such a hydrazide structure, so it will not undergo a chelation reaction with metal cations, ensuring the stability and reliability of its efficacy.

2. Risk of hepatotoxicity

Eltrombopag contains a biphenyl structure, which is potentially hepatotoxic and may cause damage to the patient's liver. In fact, taking eltrombopag may lead to risks such as elevated liver enzymes and liver failure. Avatrombopag does not have this hepatotoxic group, so it has better safety performance and is especially suitable for patients with liver dysfunction.

3. Pharmacokinetic properties

Avatrombopag and eltrombopag also differ pharmacokinetically. Avatrombopag does not undergo UGT metabolism, so it has no hepatotoxicity. Its half-life is relatively long at 14.7 hours, allowing it to be taken once a week, thus improving the convenience of medication for patients. Eltrombopag has a relatively short half-life and needs to be taken once a day, and it is mainly excreted through urine. Patients with renal insufficiency may need to adjust the dose or avoid its use.

4. Indications and efficacy

Alvatrombopag and eltrombopag are both thrombopoietin receptor agonists, but their indications and efficacy are also different. Eltrombopag is mainly used to treat idiopathic thrombocytopenic purpura (ITP) and thrombocytopenia caused by severe hepatitis. Avatrombopag is more commonly used for the treatment of chronic liver disease-related thrombocytopenia in adults who are scheduled to undergo invasive examinations or surgeries, as well as chronic immune thrombocytopenia (ITP) who have had poor response to previous treatments. In addition, avatrombopag is also able to increase and maintain platelet counts within the target range under long-term administration, with good safety and tolerability.

5. Precautions for use

Because of the risk of hepatotoxicity associated with eltrombopag, patients need regular monitoring of liver function to ensure safety. Avatrombopag does not require special liver function monitoring, and its absorption is not affected by food, making its administration more convenient. In addition, the use of Eltrombopag is also subject to dietary restrictions. Taking it with foods containing metal cations such as calcium and magnesium will affect its absorption. Avatrombopag does not have this restriction and can be taken with food.

6. Use by special groups

Avatrombopag can be used in children and adolescents, and its safety and effectiveness have been demonstrated. However, the use of eltrombopag and heltrombopag in pediatric patients has not been well studied and therefore its use in pediatric patients is limited.

When choosing to use these two drugs, doctors should comprehensively consider the patient's specific condition, physical condition, and personal needs to ensure that the most suitable treatment option is selected for the patient. At the same time, patients should strictly follow medical instructions when using these drugs and undergo relevant examinations regularly to ensure the safety and effectiveness of treatment.